Literature DB >> 33036052

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers.

Andreas Stallmach1, Andreas Sturm2, Irina Blumenstein3, Ulf Helwig4, Sibylle Koletzko5, Petra Lynen6, Carsten Schmidt7, Axel Dignass8, Torsten Kucharzik9.   

Abstract

The COVID-19 pandemic is a global outbreak of new onset infections with the SARS-CoV-2 virus. To date, more than 3.4 million people have been infected throughout the world. In Germany, approximately 450,000 patients suffer from inflammatory bowel disease; these patients generally require continuous expert care and support. Against the background of a rapidly accumulating knowledge base on SARS-CoV-2, 68 expert authors of the current DGVS guidelines for Crohn's disease and ulcerative colitis took part in a virtual meeting to compile up-to-date, practice-orientated recommendations aimed at improving the care of patients with IBD. These recommendations address the risk of infection, including the risk for specific patient groups, the possible course of the disease, and consequences for pharmacological and surgical therapies of the underlying disease, as well as general measures for infection prevention and adjuvant prophylactic and therapeutic options. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33036052     DOI: 10.1055/a-1234-8079

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  2 in total

1.  Mind-body-medicine and comprehensive lifestyle-modification in patients with Crohn's disease-Feasibility of a randomized controlled trial under pandemic circumstances.

Authors:  Nina Bauer; Claudia Löffler; Özlem Öznur; Christine Uecker; Thomas Keil; Jost Langhorst
Journal:  Front Integr Neurosci       Date:  2022-08-23

Review 2.  [What is confirmed in the treatment of chronic inflammatory bowel diseases].

Authors:  Carolin F Manthey; Dominik Reher; Samuel Huber
Journal:  Internist (Berl)       Date:  2021-11-02       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.